You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

The Patient Journey in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Best Practices for Communication and Shared Decision-making

  • Authors: Giuseppe Curigliano, MD; Karen Drucker, NP, RN; Sara A. Hurvitz, MD, FACP
  • CME / CE Released: 11/28/2022
  • Valid for credit through: 11/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, surgeons, and obstetricians/gynecologists.

The goal of this activity is for learners to better communicate with patients who have hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) when discussing adjuvant therapy, with the aim of improving patient adherence to and persistence of therapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Communication with patients about their risk of recurrence
    • Communication with patients regarding possible AEs
  • Have greater competence related to
    • Communicating with patients about adjuvant treatment options
    • Monitoring patients on adjuvant treatment for high-risk HR-positive/HER2-negative EBC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

-

Disclosures for additional planners can be found here.


Faculty

  • Giuseppe Curigliano, MD

    Professor
    University of Milan
    Director of the Division of Early Drug Development
    European Institute of Oncology
    Milan, Italy

    Disclosures

    Giuseppe Curigliano, MD, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bristol Myers Squibb; Celcuity; Daiichi Sankyo; Gilead Sciences; Lilly; Menarini; Merck; Novartis; Roche; Sanofi; Seagen Inc.
    Speaker or member of speakers bureau for: Daiichi Sankyo; Lilly
    Research funding from: Merck

  • Karen Drucker, NP, RN

    Nurse Practitioner
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

    Disclosures

    Karen Drucker, NP, has no relevant financial relationships.

  • Sara A. Hurvitz, MD, FACP

    Professor of Medicine
    Director, Breast Cancer Clinical Trials Program
    Division of Hematology-Oncology
    David Geffen School of Medicine, UCLA
    Los Angeles, California, United States
    Medical Director, Clinical Research Unit
    Jonsson Comprehensive Cancer Center
    Santa Monica, California, United States

    Disclosures

    Sara A. Hurvitz, MD, FACP, has the following relevant financial relationships:
    Contracted researcher for: Ambrx; Amgen; AstraZeneca; Arvinas; Bayer; CytomX, Daiichi Sankyo; Dignitana; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Immunomedics; Eli Lilly; Macrogenics; Novartis; OBI Pharma; Orinove; Pfizer; Phoenix Molecular Designs, Ltd; Pieris; PUMA; Radius; Sanofi; Seagen Inc; Zymeworks

Editors

  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Deborah Grainger, PhD, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

The Patient Journey in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Best Practices for Communication and Shared Decision-making

Authors: Giuseppe Curigliano, MD; Karen Drucker, NP, RN; Sara A. Hurvitz, MD, FACPFaculty and Disclosures

CME / CE Released: 11/28/2022

Valid for credit through: 11/28/2023

processing....

Transcripción en español

Download the pdf.

 

« Return to: The Patient Journey in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Best Practices for Communication and Shared Decision-making
  • Print